We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Radiofrequency Ablation System Treats Spinal Tumors

By HospiMedica International staff writers
Posted on 14 Oct 2013
A highly precise ablation system permits minimally invasive targeted tumor necrosis of metastatic spinal tumors.

The Spinal Tumor Ablation with Radiofrequency (STAR) system uses targeted radiofrequency ablation (t-RFA) to deliver energy that heats and destroys the metastatic spinal tumor, providing rapid and lasting pain relief in a single treatment. More...
The bipolar device provides the physician with real-time procedural information using temperature-measuring thermocouples that monitor and adjust, in real time, the RF energy being delivered to the tumor, maximizing tumor destruction while minimizing the risk of impacting healthy surrounding tissue.

During the procedure, the tumor is approached in a uniportal manner with a series of navigational osteotomes and the steerable ablation Instrument. Once positioned appropriately, the articulating electrode of the ablation Instrument is deployed, and RF energy is delivered from the generator directly into the tumor. Local temperatures in and around the ablation zone are continuously displayed and physician controlled at all times. When the required number of RF ablation cycles has been reached, the pedicle access may be closed.

Following ablation with the STAR system, the vertebrae are stabilized with ultra-high viscosity cement; the minimally invasive procedure generally takes about an hour. Unlike patients being treated with radiation therapy for metastatic spinal tumors, those who undergo RF ablation therapy for the same reasons may have no need to delay their systemic and primary cancer regimens. The STAR system is a product of DFine (San Jose, CA, USA), and has received the European community CE mark of approval.

“We are very excited to bring this new treatment modality to Europe so that the hundreds of thousands of patients suffering from painful spinal tumors can receive the rapid pain relief that patients here in the US have experienced. This represents a significant milestone for the company,” said Greg Barrett, CEO of DFine.

Metastatic spinal tumors are a growth of cell mass in or around the vertebra near the spinal cord. It is estimated that 30%–40% of cancer patients will likely develop metastatic spinal tumors. Currently, patients suffering from painful spinal tumors have limited options, and many live in excruciating pain, unable to perform activities of daily living.

Related Links:
DFine


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.